# Clinical Cases: Cancer Pharmacology

## Case 1: Managing Chemotherapy-Induced Nausea and Neutropenic Fever

### Patient Demographics
- **Age:** 52 years
- **Sex:** Female
- **Occupation:** High school principal (on medical leave)

### Chief Complaint
"I have a fever and I just finished my first chemotherapy last week."

### History of Present Illness
A 52-year-old woman with newly diagnosed Stage IIB breast cancer (ER+/PR+/HER2-) presents to the emergency department with fever. She received her first cycle of dose-dense AC chemotherapy (doxorubicin + cyclophosphamide) 10 days ago. Despite taking antiemetic medications, she experienced significant nausea and vomiting for the first 4 days and had difficulty eating. She developed progressive fatigue over the past few days and today noticed a temperature of 38.6C (101.5F) at home. She has no localizing symptoms: no cough, dysuria, diarrhea, or skin changes. She has an implanted port for chemotherapy access.

### Chemotherapy Regimen
**Dose-Dense AC (every 2 weeks x 4 cycles):**
- Doxorubicin 60 mg/m2 IV
- Cyclophosphamide 600 mg/m2 IV
- Pegfilgrastim 6 mg SC day 2 (G-CSF support)

**Antiemetic Regimen Prescribed:**
- Ondansetron 8 mg PO BID x 3 days
- Dexamethasone 8 mg PO daily x 3 days
- Aprepitant 125 mg day 1, then 80 mg days 2-3
- Prochlorperazine 10 mg PO q6h PRN

### Physical Examination
- **Vital Signs:** T 38.9C (102F), BP 100/62 mmHg, HR 108 bpm, RR 20/min
- **General:** Ill-appearing, fatigued
- **HEENT:** Oral mucosa with mild mucositis; no thrush
- **Port site:** No erythema, tenderness, or drainage
- **Lungs:** Clear to auscultation
- **Abdomen:** Soft, non-tender
- **Skin:** No rashes, cellulitis, or perianal abnormalities

### Workup
**Laboratory Studies:**
| Test | Result | Reference | Interpretation |
|------|--------|-----------|----------------|
| WBC | 0.8 x 10^9/L | 4.5-11.0 | **Severely low** |
| **ANC** | **0.2 x 10^9/L** | 1.5-8.0 | **Severe neutropenia** |
| Hemoglobin | 10.2 g/dL | 12-16 | Mild anemia |
| Platelets | 145 x 10^9/L | 150-400 | Low-normal |
| Creatinine | 0.9 mg/dL | 0.6-1.2 | Normal |
| Lactate | 1.8 mmol/L | 0.5-2.2 | Normal |

**Additional Studies:**
- Blood cultures x 2 sets (peripheral and from port): Pending
- Urinalysis: Negative
- Chest X-ray: No infiltrates

### Diagnosis
**Febrile Neutropenia**

**Definition:**
- Fever: Single temperature >= 38.3C (101F) OR >= 38.0C (100.4F) sustained for >= 1 hour
- Neutropenia: Absolute Neutrophil Count (ANC) < 500 cells/mcL OR < 1000 cells/mcL with expected decline to < 500

This patient has ANC of 200 and fever of 38.9C = **Medical Emergency**

### Pathophysiology of Chemotherapy-Induced Neutropenia

**Mechanism:**
- Chemotherapy is cytotoxic to rapidly dividing cells
- Bone marrow hematopoietic stem cells are highly proliferative
- Neutrophil precursors are damaged, reducing production
- Nadir (lowest point) typically occurs 7-14 days after chemotherapy
- Duration depends on regimen; recovery usually within 1-2 weeks

**Why Neutropenic Fever is Dangerous:**
- Neutrophils are primary defense against bacterial and fungal infections
- Without neutrophils, minor infections become life-threatening
- Typical inflammatory signs (pus, infiltrates) may be ABSENT
- Bacteria can rapidly disseminate (sepsis, shock)

### Treatment

**FEBRILE NEUTROPENIA MANAGEMENT:**

**1. Immediate Empiric Antibiotics (within 1 hour of presentation):**
- **Antipseudomonal beta-lactam monotherapy:**
  - Cefepime 2 g IV every 8 hours, OR
  - Piperacillin-tazobactam 4.5 g IV every 6 hours, OR
  - Meropenem 1 g IV every 8 hours (if penicillin allergy or ESBL concern)

**Why Antipseudomonal Coverage?**
- Pseudomonas aeruginosa causes rapid, lethal infections in neutropenic patients
- Must cover gram-negative organisms including Pseudomonas from the start
- Can narrow later based on culture results

**2. Additional Coverage Considerations:**
- **Add vancomycin if:**
  - Port site infection suspected
  - Skin/soft tissue infection
  - Hemodynamic instability
  - Known MRSA colonization
  - Mucositis (oral flora including Streptococcus viridans)
- This patient has mild mucositis - add vancomycin 1 g IV every 12 hours

**3. Continue Monitoring:**
- Serial vital signs
- Daily CBC to follow ANC recovery
- Repeat blood cultures if persistent fever

**4. G-CSF Consideration:**
- She already received pegfilgrastim after chemotherapy
- Additional G-CSF generally not indicated for treatment of established febrile neutropenia
- Role is in PRIMARY PREVENTION, not treatment

### Understanding Antiemetic Pharmacology

**Why Did She Have Breakthrough Nausea?**

AC chemotherapy is **highly emetogenic** (>90% risk without prophylaxis)

**Three Phases of Chemotherapy-Induced Nausea:**
| Phase | Timing | Primary Mediator | Best Treatment |
|-------|--------|------------------|----------------|
| Acute | 0-24 hours | Serotonin (5-HT3) | 5-HT3 antagonist (ondansetron) |
| Delayed | 24-120 hours | Substance P (NK-1) | NK-1 antagonist (aprepitant) |
| Anticipatory | Before chemo | Conditioned response | Benzodiazepines |

**Optimal Triple Antiemetic Regimen for Highly Emetogenic Chemo:**
1. **5-HT3 antagonist:** Ondansetron 8 mg or palonosetron 0.25 mg
2. **NK-1 antagonist:** Aprepitant 125/80/80 mg or fosaprepitant IV
3. **Dexamethasone:** 12 mg day 1, then 8 mg days 2-4
4. *Consider adding:* Olanzapine 5-10 mg days 1-4

**This patient's regimen was appropriate but may benefit from:**
- Olanzapine addition for breakthrough nausea
- Extended dexamethasone (4 days instead of 3)
- PRN lorazepam for anticipatory nausea

### Understanding G-CSF (Filgrastim/Pegfilgrastim)

**Mechanism:**
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Binds G-CSF receptor on myeloid precursors
- Stimulates neutrophil production and maturation
- Accelerates neutrophil release from bone marrow
- Enhances neutrophil function

**Indications for Primary Prophylaxis:**
- Regimens with >= 20% risk of febrile neutropenia
- Dose-dense regimens (like this patient's)
- Patient factors increasing risk (age > 65, comorbidities)

**Timing:**
- Filgrastim: Start 24-72 hours after chemo, continue until ANC recovery
- Pegfilgrastim: Single dose 24-72 hours after chemo (long-acting)

**She received pegfilgrastim but still developed neutropenia because:**
- Even with G-CSF support, nadir neutropenia still occurs
- G-CSF reduces depth and duration of nadir but doesn't prevent it entirely
- Her ANC at day 10 represents the nadir period

### Hospital Course
- Blood cultures returned positive for coagulase-negative Staphylococcus (likely port-related)
- Continued vancomycin; cefepime narrowed after cultures finalized
- ANC recovered to 1,500 by hospital day 4
- Discharged to complete oral antibiotics

### Follow-up Recommendations
**For Future Chemotherapy Cycles:**
1. Continue pegfilgrastim (already on)
2. Enhanced antiemetic regimen: Add olanzapine 10 mg days 1-4
3. Education on fever precautions: Check temperature if feeling unwell; come to ED immediately if >= 38.0C
4. Dose modification may be considered if recurrent severe neutropenia

### Clinical Pearl
Febrile neutropenia is an oncologic emergency requiring empiric broad-spectrum antibiotics within 1 hour of presentation. The most important coverage is against gram-negative bacteria including Pseudomonas. Even patients receiving G-CSF prophylaxis can develop neutropenia. Chemotherapy-induced nausea involves multiple pathways - highly emetogenic regimens require triple antiemetic therapy targeting serotonin (5-HT3 antagonist), substance P (NK-1 antagonist), and inflammation (dexamethasone). Adding olanzapine improves control of delayed nausea. Prevention of febrile neutropenia with G-CSF and prevention of nausea with appropriate antiemetics are critical for maintaining chemotherapy dose intensity and patient quality of life.

### Clinical Image
![Chemotherapy Administration](case_01_image.jpg)

*Image depicting chemotherapy administration through an implanted port. Proper antiemetic prophylaxis and G-CSF support are essential components of chemotherapy management to prevent nausea and reduce the risk of febrile neutropenia.*

**Image Source:** Wikimedia Commons - "Chemotherapy infusion"
**License:** CC BY-SA 4.0
**URL:** https://commons.wikimedia.org/wiki/File:Chemotherapy_infusion.jpg

---

## Case 2: Targeted Therapy in HER2-Positive Breast Cancer

### Patient Demographics
- **Age:** 48 years
- **Sex:** Female
- **Occupation:** Nurse practitioner

### Chief Complaint
"I found a lump in my breast and the biopsy shows cancer."

### History of Present Illness
A 48-year-old woman presents after self-detecting a left breast mass during self-examination. Mammogram and ultrasound confirmed a 2.5 cm spiculated mass in the upper outer quadrant with suspicious axillary lymph nodes. Core needle biopsy revealed invasive ductal carcinoma. Pathology shows: Grade 3, ER-negative, PR-negative, HER2-positive (IHC 3+ confirmed by FISH with HER2/CEP17 ratio 4.2). PET-CT staging shows no distant metastases.

### Final Staging
- **Clinical Stage:** IIB (T2N1M0)
- **Tumor Characteristics:** Triple-negative for hormone receptors, HER2-positive
- **Grade:** 3 (poorly differentiated)

### Understanding HER2 Biology

**What is HER2?**
- Human Epidermal Growth Factor Receptor 2
- Member of ErbB receptor tyrosine kinase family
- Overexpressed/amplified in ~15-20% of breast cancers
- Associated with aggressive tumor behavior

**HER2 Signaling Pathway:**
1. HER2 dimerizes with other ErbB family members (HER1, HER3, HER4)
2. Activates downstream signaling cascades:
   - RAS/MAPK pathway (proliferation)
   - PI3K/AKT pathway (survival, anti-apoptosis)
3. Results in increased cell proliferation, survival, and metastatic potential

**HER2 Testing:**
| Method | Positive Result | Interpretation |
|--------|-----------------|----------------|
| IHC | 3+ | HER2 positive (treat) |
| IHC | 2+ | Equivocal (need FISH) |
| IHC | 0, 1+ | HER2 negative |
| FISH | Ratio >= 2.0 | HER2 amplified (treat) |

This patient is IHC 3+ with FISH ratio 4.2 = Strongly HER2-positive

### Treatment Plan

**Neoadjuvant (Pre-Surgical) Chemotherapy + HER2-Targeted Therapy:**

**TCHP Regimen (every 3 weeks x 6 cycles):**
- **Docetaxel (T):** 75 mg/m2 IV - Taxane (microtubule stabilizer)
- **Carboplatin (C):** AUC 6 IV - Platinum (DNA crosslinker)
- **Trastuzumab (H):** 8 mg/kg loading, then 6 mg/kg IV - Anti-HER2 antibody
- **Pertuzumab (P):** 840 mg loading, then 420 mg IV - Anti-HER2 antibody

### Understanding HER2-Targeted Agents

**1. Trastuzumab (Herceptin) - Monoclonal Antibody**

**Mechanism:**
- Binds to extracellular domain IV of HER2 receptor
- Prevents HER2 dimerization and downstream signaling
- Induces antibody-dependent cellular cytotoxicity (ADCC)
- Downregulates HER2 receptor expression
- Inhibits cleavage of HER2 extracellular domain

**Key Toxicity: CARDIOTOXICITY**
- Mechanism: HER2 signaling important for cardiomyocyte survival
- Manifests as decreased LVEF, heart failure
- Usually reversible (unlike anthracycline cardiotoxicity)
- **Monitoring:** Echocardiogram or MUGA before starting and every 3 months
- **Hold if LVEF drops >= 16% from baseline or below normal with >= 10% drop**

**2. Pertuzumab (Perjeta) - Monoclonal Antibody**

**Mechanism:**
- Binds to extracellular domain II of HER2 (different epitope than trastuzumab)
- Prevents HER2 heterodimerization with HER3
- Complementary to trastuzumab: "Dual HER2 blockade"
- Also induces ADCC

**Key Points:**
- Used in combination with trastuzumab (not monotherapy)
- Improves pathologic complete response rates in neoadjuvant setting
- Improves survival in metastatic setting
- Similar cardiac monitoring as trastuzumab

**3. Additional HER2-Targeted Agents (For Reference):**

| Agent | Type | Mechanism | Use |
|-------|------|-----------|-----|
| Trastuzumab | mAb | Binds HER2 domain IV | First-line |
| Pertuzumab | mAb | Binds HER2 domain II | First-line (with T) |
| T-DM1 (Kadcyla) | ADC | Trastuzumab + emtansine (chemotherapy) | After trastuzumab failure |
| T-DXd (Enhertu) | ADC | Trastuzumab + deruxtecan (topoisomerase inhibitor) | Metastatic |
| Lapatinib | TKI | Small molecule HER1/HER2 inhibitor | Metastatic |
| Tucatinib | TKI | Selective HER2 inhibitor | Metastatic (CNS activity) |
| Neratinib | TKI | Pan-HER inhibitor | Extended adjuvant |

**ADC = Antibody-Drug Conjugate:**
- Monoclonal antibody linked to cytotoxic payload
- Antibody targets cancer cell
- Internalized, releases chemotherapy inside cell
- "Targeted chemotherapy delivery"

### Pre-Treatment Workup

**Required Before Starting TCHP:**
1. **Echocardiogram:** LVEF 62% (normal >= 50%)
2. **CBC, CMP:** Normal
3. **Hepatitis B serology:** Negative (trastuzumab can cause reactivation)
4. **Fertility counseling:** Chemotherapy causes ovarian toxicity; discuss egg preservation

### Treatment Course

**Neoadjuvant Therapy Completed:**
- 6 cycles TCHP completed
- Tolerated well; mild nausea, fatigue, neuropathy
- Repeat echo after cycle 3 and 6: LVEF stable at 58%

**Surgery:**
- Lumpectomy + sentinel lymph node biopsy
- **Pathology: Complete pathologic response (pCR)** - No residual invasive cancer
- pCR is associated with excellent long-term outcomes in HER2+ disease

**Adjuvant (Post-Surgical) Therapy:**
- Continue trastuzumab + pertuzumab to complete 1 year of HER2-targeted therapy
- Radiation therapy to breast
- No hormonal therapy needed (ER/PR negative)

### Monitoring and Follow-up

**Cardiac Monitoring:**
- Echo every 3 months during HER2-targeted therapy
- Continue monitoring 6-12 months after completion

**If LVEF Decreases:**
- Drop of >= 16% from baseline OR
- LVEF below normal with >= 10% drop
- **Hold trastuzumab/pertuzumab**
- Repeat echo in 4 weeks
- Can rechallenge if LVEF recovers
- Consider cardiology consultation, start ACE inhibitor/beta-blocker

### Clinical Pearl
HER2-positive breast cancer, once associated with poor prognosis, has been transformed by HER2-targeted therapies. Trastuzumab revolutionized treatment and significantly improved survival. Adding pertuzumab provides "dual HER2 blockade" by binding different epitopes and preventing HER2/HER3 dimerization. Pathologic complete response (no residual invasive cancer after neoadjuvant therapy) is a strong predictor of excellent outcomes. The main toxicity concern with HER2-targeted antibodies is cardiotoxicity, requiring regular LVEF monitoring. Unlike anthracycline-induced cardiomyopathy (permanent damage via oxidative stress), trastuzumab cardiotoxicity is usually reversible with drug interruption. For patients who progress on trastuzumab, antibody-drug conjugates (T-DM1, T-DXd) deliver cytotoxic payloads directly to HER2-expressing cells.

### Clinical Image
![HER2 Immunohistochemistry](case_02_image.jpg)

*Immunohistochemistry staining for HER2 in breast cancer tissue. HER2 3+ staining shows strong complete membrane staining, indicating HER2 overexpression and eligibility for HER2-targeted therapy.*

**Image Source:** Wikimedia Commons - "HER2 immunohistochemistry"
**License:** CC BY-SA 4.0
**URL:** https://commons.wikimedia.org/wiki/File:HER2_immunohistochemistry.jpg

---